To include your compound in the COVID-19 Resource Center, submit it here.

Blueprint proposes $275M follow-on after ASH gains

Blueprint Medicines Corp. (NASDAQ:BPMC) gained $16.46 (23%) to $88.32 on Monday after reporting its lead candidate, avapritinib (formerly BLU-285), led to an overall response rate (ORR) of

Read the full 272 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE